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Adeno-associated virus (AAV) has shown great promise 
as a gene therapy vector in multiple aspects of preclinical 
and clinical applications. Many developments including 
new serotypes as well as self-complementary vectors are 
now entering the clinic. With these ongoing vector devel-
opments, continued effort has been focused on scalable 
manufacturing processes that can efficiently generate 
high-titer, highly pure, and potent quantities of rAAV vec-
tors. Utilizing the relatively simple and efficient transfec-
tion system of HEK293 cells as a starting point, we have 
successfully adapted an adherent HEK293 cell line from 
a qualified clinical master cell bank to grow in animal 
component-free suspension conditions in shaker flasks 
and WAVE bioreactors that allows for rapid and scalable 
rAAV production. Using the triple transfection method, 
the suspension HEK293 cell line generates greater than 
1 × 105 vector genome containing particles (vg)/cell or 
greater than 1 × 1014 vg/l of cell culture when harvested 
48 hours post-transfection. To achieve these yields, a 
number of variables were optimized such as selection of 
a compatible serum-free suspension media that supports 
both growth and transfection, selection of a transfection 
reagent, transfection conditions and cell density. A uni-
versal purification strategy, based on ion exchange chro-
matography methods, was also developed that results in 
high-purity vector preps of AAV serotypes 1–6, 8, 9 and 
various chimeric capsids tested. This user-friendly pro-
cess can be completed within 1 week, results in high full 
to empty particle ratios (>90% full particles), provides 
postpurification yields (>1 × 1013 vg/l) and purity suitable 
for clinical applications and is universal with respect to 
all serotypes and chimeric particles. To date, this scalable 
manufacturing technology has been utilized to manu-
facture GMP phase 1 clinical AAV vectors for retinal neo-
vascularization (AAV2), Hemophilia B (scAAV8), giant 
axonal neuropathy (scAAV9), and retinitis pigmentosa 
(AAV2), which have been administered into patients. In 
addition, we report a minimum of a fivefold increase in 
overall vector production by implementing a perfusion 
method that entails harvesting rAAV from the culture 
media at numerous time-points post-transfection.
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INTRODUCTION
The benefits of using adeno-associated virus (AAV) for gene ther-
apy include long-term gene expression, the inability to autono-
mously replicate without a helper virus, transduction of dividing 
and nondividing cells, and the lack of pathogenicity from wild-
type infections. A number of phase 1 and phase 2 clinical trials 
utilizing AAV have been performed worldwide.1,2 However, many 
preclinical studies and clinical trials have demonstrated a num-
ber of challenges that will need to be addressed to sustain rAAV 
use for human gene therapy.2 One major challenge is establishing 
large-scale manufacturing technologies in accordance with cur-
rent good manufacturing practices (cGMP) to yield the purified 
vector quantities needed for the expanding clinical need. The suc-
cess of generating a scalable production technology relies heavily 
on understanding the basic biology of AAV in regard to gener-
ating reagents such as cell lines, plasmids, or recombinant viral 
vectors that when used together, will closely mimic wild-type (wt) 
AAV production.
The generation of rAAV vectors entails encapsidation of a 
therapeutic gene of interest utilizing the wt replication (rep) and 
capsid (cap) genes. rAAV production requires delivery of the pro-
viral (vector DNA) construct, the rep and cap genes specific to the 
serotype of interest and Adenovirus (Ad) or Herpes Simplex Virus 
(HSV) helper virus functions.3,4
Adenovirus (Ad) and HSV have been shown to be necessary 
for rAAV replication. In regard to the Ad helper virus, the E1a, 
E1b, E2a, E4orf6, and VA RNA genes were determined to supply 
the helper functions necessary for rAAV production.5 Infection of 
Ad into producer cells to generate rAAV was effective in producing 
rAAV, but a consequence was that it also produced Ad particles. A 
significant improvement in the evolution of rAAV production was 
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the introduction of the triple plasmid transfection method.5 This 
method used an AAV serotype-specific rep and cap plasmid as well 
as the vector DNA plasmid, but eliminated the use of Ad infection 
by supplying the essential Ad genes on a third plasmid (pXX6). 
Supplying the Ad helper genes on the pXX6 plasmid eliminated 
Ad production in the transfected cells yielding only rAAV vec-
tor. Multiplasmid transient transfection of adherent HEK293 cells 
remains the most widely used method for rAAV production.5–7
Advances and novel approaches in rAAV production have 
been made recently that have allowed some laboratories to move 
away from production using adherent HEK293 cells and move 
toward scalable technologies. These novel approaches use alter-
nate helper viruses and nonmammalian cells. The dual HSV infec-
tion system has been shown to generate 5 × 104 to 1 × 105 vg/cell 
with low particle to infectivity ratios.8–12 rAAV production using 
the insect baculovirus Autographa californica nuclear polyhedro-
sis (baculovirus expression vector system (BEVS)) has also been 
investigated in Spodoptera frugiperda (Sf9) cells.13–19 Yields of up 
to 5 × 104 vg/cell have been reported using BEVS.1
A few recent studies have reported rAAV production from 
mammalian HEK293 cells adapted to grow in serum-free sus-
pension media.20–22 Park et al. and Durocher et al. demonstrated 
that approximately 1.4 × 104 and 3 × 104 vg/cell respectively were 
generated using their optimized serum-free suspension HEK293 
cell transient transfection production systems. Common with 
these studies is the fact that the yield of vector continues to be 
the impediment and significantly below the vg/cell generated via 
transfection of adherent HEK293 cells in the presence of serum 
and the rHSV and BEVS production systems.
In this report, we demonstrate that it is possible to adapt a 
HEK293 cell line in animal component-free conditions to gener-
ate greater than 1 × 105 vector genome containing particles per cell 
and yield greater than 1 × 1013 purified rAAV from 1 l of transiently 
transfected cell culture. The adaptation and optimization spanned 
over a 2-year period. However, the resulting cell clone and con-
ditions have remained stable over thousands of production runs, 
which include both preclinical and clinical manufacturing. The 
manufacturing system can be used to produce and purify numer-
ous rAAV serotypes and chimeric capsids (e.g., 1–9) with signifi-
cantly reduced empty particles. The system has been successfully 
adapted to WAVE bioreactors and small scale stir tank bioreactors 
demonstrating a seamless transition from shaker flasks and estab-
lishing that the transient transfection manufacturing technology 
is scalable. Furthermore, we have shown that it is possible to con-
tinuously harvest nonheparin binding rAAV serotypes from the 
suspension culture media over a 6-day period.
RESULTS
Development of a suspension HEK293 cell line
The purpose of this work was to generate a scalable manufactur-
ing technology to produce high-titer and highly pure rAAV using 
transient transfection technology and mammalian HEK293 cells. 
To begin, an adherent HEK293 cell line from our GMP facil-
ity’s qualified master cell bank (derived from a clone previously 
selected for high transfection efficiency and rAAV production) 
was adapted to grow in serum-free suspension conditions as 
described in the methods section. After adaptation to growth in 
animal component-free and antibiotic-free suspension conditions 
and selection of a compatible serum-free suspension medium, the 
suspension HEK293 cell line maintained its ability for high trans-
fection efficiency and rAAV production.
Optimization of transfection conditions using 
polyethyleneimine Max
Previously, our laboratory utilized polyethyleneimine (PEI) (lin-
ear 25-kDa) for transfection of adherent HEK293 cells.23 PEI was 
selected for use in this study because it is well-tolerated by HEK293 
cells, able to transfect HEK293 cells very efficiently, does not require 
a media change after transfection, and is very inexpensive compared 
to commercially available lipid transfection reagents. It was recently 
shown that removal of the residual N-acyl moieties from commer-
cial linear 25-kDa PEI enhanced its plasmid DNA delivery efficiency 
21 times in vitro, as well as 10,000 times in mice with a 1,500-fold 
enhancement in lung specificity.24 Although the fully deacylated 
forms of PEI that Thomas et al. generated are not manufactured and 
available commercially, Polysciences supplies PEI Max which is built 
from the same linear 25-kDA polymer, but contains more than 11% 
additional free nitrogens. Tested side by side and consistent with 
data from Thomas et al., PEI Max was superior in transfection effi-
ciency than PEI on our adherent and suspension HEK293 cells (data 
not shown). Therefore, all transfection optimization studies on the 
suspension HEK293 cells were conducted using PEI Max.
Two of the major requirements for production of rAAV using 
transient transfection are determining the optimal plasmid ratios of 
the three plasmids and the transfection reagent to total DNA ratio. The 
suspension HEK293 cells were initially grown in SFM4Transfx-293 
media and were seeded at 1 × 106 viable cells/ml in a 30 ml volume 
in 125 ml shaker flasks on the day of transfection. Various ratios of 
XX680:pXR2:TReGFP were tested with PEI Max to DNA ratios of 
2:1 and 4:1 with 1 µg DNA/ml of cells and incubated at room temper-
ature for 10–15 minutes. As shown in Figure 1a, the plasmid molar 
ratio of 2:1.5:1 with a PEI Max to DNA ratio of 2:1 generated the 
most vector genomes (vg)/cell. Vg/cell from cell lysates were deter-
mined using Quantitative PCR (qPCR) methods as described in the 
methods section. It was evident that the PEI Max to DNA ratio of 
4:1 generated the least amount of vg/cell at all plasmid ratios tested. 
This was most likely due to a lower cell viability post-transfection, 
detected by the Beckman ViCell XR Viability analyzer, suggesting a 
level of toxicity was reached with PEI Max. In addition, the 4:1 PEI 
Max to DNA ratio led to larger cell aggregates after transfection. This 
occurrence was most likely due to an increased concentration of PEI 
Max/DNA complexes in the cell culture, which have a net positive 
charge leading to cell to cell interaction. Experiments described from 
this point on will be utilizing the plasmid ratio of 2:1.5:1 along with 
PEI Max to DNA ratio of 2:1.
A number of lipid-based transfection protocols describe the 
importance of the transfection cocktail volume. To determine the 
impact of transfection cocktail volume on transfection efficiency 
and vector production using PEI Max, transfection cocktail vol-
umes of 2, 5, and 10% were selected. The % volume is based on 
the final cell culture volume in the shaker flask. As illustrated in 
Figure 1b, a 5% transfection cocktail volume was shown to have 
the better transfection efficiency (based on green fluorescent pro-
tein (GFP) flow cytometry) and generated the most vg/cell.
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Optimization of cell density and plasmid DNA 
concentrations
Prior to initiating these studies, we began using the FreeStyle F17 
serum-free suspension media from Invitrogen that supported bet-
ter growth of our cell clone, increased transfection efficiency and 
increased vector production/cell. The suspension HEK293 cells 
were diluted in the FreeStyle F17 media to 1 × 106 and 2 × 106 via-
ble cells/ml to achieve a final cell culture volume of 30 ml. 1, 1.5, 
and 2 µg/ml of plasmid DNA were utilized in this set of experi-
ments. Based on the data shown in Figure 2a, it was evident that 
the rAAV vector production was optimal when the cell density 
was at 1 × 106 viable cells/ml at the time of transfection using 
1.5 µg/ml of plasmid DNA.
Over the course of experimentation, the suspension HEK293 
cells were passaged a number of times and when low, medium 
and high passage cells were available, they were transfected to 
determine if cell culture age impacted transfection efficiency 
and rAAV production. As shown in Figure 2b, transfection effi-
ciency is not impacted by cell culture age, but rAAV produc-
tion per cell decreases over time suggesting that the suspension 
HEK293 cell clone that was developed should be used a maxi-
mum of 30–40 passages.
Purification of rAAV serotypes using ion exchange 
chromatography
In conjunction with the optimization of rAAV production in 
suspension HEK293 cells, we focused on AAV purification. We 
set out to develop a universal purification strategy for all AAV 
serotypes and chimeric capsids using ion exchange chromatog-
raphy. Previous studies reported that purification of different 
serotypes could be accomplished through the use of various 
ion exchange chromatography methods and resins.25–27 We 
rationalized that ion exchange chromatography, using a single 
anionic or cationic resin, could potentially be used to purify 
all serotypes through modulation of specific parameters during 
the binding and elution steps. It was previously reported that 
efficient clarification of rAAV cell lysates can be accomplished 
through the use of discontinuous iodixanol gradient purifica-
tion and that the iodixanol did not impact rAAV interaction 
with the ion exchange resin.28 We thus employed the use of a 
Figure 1  Optimization of triple transfection plasmid ratios and 
transfection cocktail volumes. (a) Varying plasmid ratios of XX680, 
pXR2 helper, and TReGFP plasmid were explored to determine optimal 
plasmid ratio for rAAV vector production. (b) Varying transfection cock-
tail volumes were tested to determine optimal transfection conditions 
with PEI Max to DNA ratio of 2:1 and an incubation time of 10–14 min-
utes. Percent volume of transfection cocktail is in reference to percent 
of final cell culture volume. These parameters were optimized using the 
SFM4Transfx-293 media (HyClone).
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Figure 2 Cell density transfection optimization experiments and 
impact of cell culture age on vector production. (a) 1 × 106 and 2 × 106 
viable cells/ml were transfected with 1, 1.5, and 2 μg of plasmid DNA 
(2:1.5:1 XX680:pXR:TR plasmid). (b) Low, medium, and high passage 
cells were transfected using optimized parameters to determine if cell 
culture age impacted transfection efficiency and rAAV production.
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modified discontinuous iodixanol gradient to clarify rAAV cell 
lysates prior to ion exchange chromatography. Buffers and pH 
chosen for the iodixanol gradient were modified to be consis-
tent with a single downstream ion exchange chromatography 
step. Figure 3a illustrates the initial experimental results using 
the modified discontinuos iodixanol gradient in conjunction 
with ion exchange chromatography. The silver stain was loaded 
with 1 × 1010 vector genome containing particles of rAAV2 
cytomegalovirus transcriptoinal promoter (CMV)-eGFP peak 
elution fractions. It is evident that the latter two elution peak 
fractions contain a small circular contaminant ranging in size 
between 5 and 10 microns (arrows in the transmission electron 
microscopy (TEM) negative stain image) with an individual/
subunit molecular weight ranging between 20–25 kDa. This 
contaminant was present in all rAAV serotype preparations and 
therefore not common to only AAV2. Through the use of mass 
spectrometry (Applied Bioimics, Hayward, CA), the contami-
nant was identified as ferritin. Through further manipulation of 
the ion exchange chromatography step, we were able to physi-
cally separate the rAAV from the ferritin. Figure 3b depicts the 
physical separation of rAAV from the ferritin based on silver 
stain and negative stain TEM analyses of peak elution frac-
tions and downstream fractions. The modified versions of the 
discontinuous iodixanol gradient and ion exchange chroma-
tography are the downstream steps in the current purification 
process used to purify all rAAV serotype and chimeric capsid 
vectors in this report. The purification procedure is consid-
ered universal because a single set of parameters (components, 
reagent/buffer concentrations, pH, chromatography resin, and 
chromatography protocol) are used to purify all AAV serotypes 
and chimeric capsids.
Production and purification of single-stranded and 
self-complementary rAAV serotypes 1–6, 8, and 9
As described in the methods section, 1 l culture volumes or 1 × 109 
viable cells were transfected using the optimized transfection 
parameters to generate single-stranded and self-complementary 
rAAV serotypes 1–6, 8, and 9 packaging the CMV-eGFP transgene 
cassette. As shown in Table 1, the transfection efficiency (based 
on GFP flow cytometry) was greater than 70% and nearly equiva-
lent among all transfections. All of the serotypes packaging a sin-
gle-stranded genome generated around and above 1 × 105 vg/cell. 
Excluding rAAV serotype 4 (one of the lowest yielding serotypes), 
all single-stranded rAAV serotypes tested generated 8.2 × 1012 to 
3.3 × 1013 total rAAV from one liter of cell culture postpurifica-
tion and were relatively free of any proteins other than VP1, VP2, 
and VP3 as depicted in the silver stain in Figure 4a. Generally, 
self-complementary vector preps yield less total AAV vector than 
their single-stranded counterparts and are usually comprised of 
varying concentrations of both self-complementary (dimer) and 
single-stranded (monomer) genomes.29 The self-complementary 
rAAV serotypes tested generated 4.0 × 1012 to 1.3 × 1013 total rAAV 
from 1 l of cell culture postpurification. As shown in the alkaline 
gel Southern blot in Figure 4b, the rAAV particles efficiently pack-
aged a high percentage of self-complementary genomes. When 
additional self-complementary rAAV vectors were produced with 
various transgene cassettes, a majority of the genomes packaged 
were self-complementary indicating that these results are not 
exclusive to self-complementary eGFP cassettes (data not shown).
A universal cell line that is permissive to most AAV serotypes 
has not been identified. However, a modified HeLa cell line called 
HeLaRC-32 (ref. 30) can be transduced in various degrees by all 
serotypes tested. The cell line contains an integrated AAV2 rep 
Figure 3 Characterization of elution peak fractions of adeno-associated virus (AAV) after ion exchange chromatography. (a) Silver stain and 
negative stain transmission electron microscopy (TEM) images of elution peak fractions of AAV using nonoptimized elution conditions for rAAV. 
Arrows represent the major contaminant (Ferritin) on the silver stain gel and the TEM image. (b) Silver stain and negative stain TEM images of elu-
tion peak fractions of AAV using optimized elution conditions for rAAV. Silver stain and TEM images illustrate physical separation of the virions and 
the ferritin contaminants.
100k
50k
VP1
VP2
VP3
20k
100k
10 11 12 13 14 15 18 19 20
50k
20k
a b
290 www.moleculartherapy.org vol. 24 no. 2 feb. 2016
© The American Society of Gene & Cell Therapy
Scalable Manufacturing of rAAV
and cap gene and upon infection with Adenovirus, any vector cas-
sette flanked by AAV2 ITRs will be replicated. The increased eGFP 
genome copy number will elicit higher expression of eGFP, which 
can then be visualized and quantitated using fluorescence micros-
copy. As expected, a range of vg:TU ratios (Table 1) was reported 
between serotypes upon infection of HeLaRC32 cells. Since cell 
Table 1 Production and purification of single-stranded and self-complementary rAAV serotypes 1–6, 8, and 9
Vector Transfection efficiency Lysate vg/cell Total vg/l postpurification Vg:TU Full:Empty
AAV1 CMV-GFP 73.8% 9.7 × 104 1.3 × 1013 45 30.2
AAV2 CMV-GFP 71.2% 2.1 × 105 3.3 × 1013 155 26.3
AAV3 CMV-GFP 74.5% 1.1 × 105 1.1 × 1013 8 10.8
AAV4 CMV-GFP 75.6% 8.9 × 104 2.8 × 1012 14,684 64.0
AAV5 CMV-GFP 74.3% 1.9 × 105 2.8 × 1013 137 18.1
AAV6 CMV-GFP 73.6% 5.7 × 104 8.2 × 1012 17 40.0
AAV8 CMV-GFP 74.4% 1.9 × 105 3.3 × 1013 716 136.3
AAV9 CMV-GFP 73.0% 2.1 × 105 2.2 × 1013 1,350 22.8
scAAV1 CMV-GFP 78.5% 4.2 × 104 5.3 × 1012 15 99.3
scAAV2 CMV-GFP 76.6% 1.1 × 105 1.4 × 1013 88 43.4
scAAV3 CMV-GFP 79.9% 6.5 × 104 7.4 × 1012 9 11.9
scAAV4 CMV-GFP 78.2% 4.8 × 104 1.0 × 1012 9,605 14.0
scAAV5 CMV-GFP 76.6% 9.3 × 104 8.7 × 1012 50 21.1
scAAV6 CMV-GFP 77.5% 6.1 × 104 4.0 × 1012 11 34.3
scAAV8 CMV-GFP 78.2% 1.1 × 105 1.3 × 1013 651 10.3
scAAV9 CMV-GFP 76.4% 1.2 × 105 1.2 × 1013 936 31.5
scAAV, self-complementary recombinant adeno-associated virus.
Figure 4 Production and purification of single-stranded and self-complementary recombinant adeno-associated virus (rAAV) serotypes 1–6, 
8, and 9 using optimized production and purification conditions. (a) Silver stain image of single-stranded serotypes 1–6, 8, and 9 postpurifica-
tion. (b) Southern blot of alkaline agarose gel of self-complementary rAAV1–6, 8, and 9. (c) Negative stain transmission electron microscopy (TEM) 
images of rAAV serotype 1 (left image), serotype 2 (middle image), and empty rAAV2 capsids (right image). TEM images were also taken of serotypes 
3–6, 8, and 9 (images not shown). Empty particles (indicated by arrows) can be distinguished based on the electron dense center within the particle.
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lines and infectivity assays have not been established or standard-
ized for AAV, transduction assays such as or similar to this can only 
be used as a guide or measuring tool to qualitatively determine 
whether a rAAV serotype batch falls within a specific acceptance 
criteria set by the investigator. As discussed thoroughly in Aucoin 
et al., comparison of transduction or infectivity data between pub-
lications should be done with vigilance due to the variety of assays 
utilized to quantitate infectivity.1
Negative stain TEM analysis of rAAV serotypes
To assess overall purity and ratio of genome-containing (full) to 
empty particles of the single-stranded and self-complementary 
rAAV, we imaged each serotype using negative stain TEM. It is well 
known that empty particles are generated when producing rAAV 
in any of the current production technologies. Discovering purifi-
cation procedures that will effectively remove the empty particles 
from full particles are needed. Empty particles take up the negative 
stain (2% uranyl acetate) differently than the full particles making 
it possible to quantitate the number of full and empty particles in 
a vector preparation. Figure 4c depicts negative stain TEM images 
of rAAV1, rAAV2 as well as empty AAV2 particle preparation. The 
rAAV1 and rAAV2 negative stain TEM images are representative of 
the other serotypes. The CsCl density gradient purified empty AAV2 
capsids were used as a negative staining control and negative stained 
as empty capsids.31 As shown in Table 1, the overall full to empty 
particle ratio was no less than 10:1 for all serotypes tested, suggest-
ing that the purification process effectively removes empty particles.
Production of rAAV using WAVE bioreactors
Production parameters for generating rAAV in shaker flasks 
using the FreeStyle F17 serum-free suspension media have been 
optimized. The next step was to translate the optimized param-
eters to the WAVE bioreactor at various cell culture volumes to 
determine scalability. A number of WAVE bioreactor runs were 
carried out ranging in size from 4.3 to 20 l of cell culture generat-
ing different serotype vectors. When possible, shaker flask cultures 
were transfected to serve as a control to compare transfection effi-
ciency (if a GFP vector was produced) and vector production per 
liter of culture postpurification. As shown in Table 2, transfection 
efficiency was nearly equivalent between flasks and WAVE biore-
actor bags. As was shown in flasks, most WAVE bioreactor runs 
generated at least 1 × 1013 purified rAAV vectors per liter of culture 
establishing that the parameters optimized for growth, transfec-
tion and rAAV production in shaker flasks translates to WAVE 
bioreactors. In most 10- and all 20-l WAVE bioreactor produc-
tion runs, greater than 1 × 1014 purified ss and scAAV vectors were 
recovered.
Continuous rAAV harvesting from suspension media
AAV was found to be secreted by an unknown mechanism into 
cell culture media using adherent HEK293 cells and harvesting 
rAAV from the media at a late time-point post-transfection.32–34 
This concept was explored using the suspension HEK293 produc-
tion system described in this report with the exception that media 
was harvested and replaced at various time points to reflect a dis-
continuous harvest of rAAV to maximize the output of the pro-
duction system from a single transfection. Flasks containing 30 ml 
cultures of suspension HEK293 cells at 1 × 106 cells/ml were trans-
fected to produce rAAV8 and rAAV9 CMV-eGFP. Forty-eight 
hours post-transfection, cell cultures were pelleted by low-speed 
centrifugation and the media removed for titering of DNase-
resistant particles by dot blot and qPCR. The cell pellets were 
Table 2 WAVE bioreactor production yields of single-stranded and self-complementary rAAV vectors
Vector
Cell culture 
volume in flask
Cell culture volume 
in WAVE bioreactor Transfection efficiency Total vg yield vg/l
AAV2 CMV-GFP 1 l – 78.3% 2.3 × 1013 2.3 × 1013
– 5 l 75.0% 1.4 × 1014 2.7 × 1013
AAV9 CBA-GFP 4 × 1l – 64.6% 6.7 × 1013 1.7 × 1013
– 4.3 63.4% 4.3 × 1013 1.0 × 1013
scAAV2i8 CMV-GFP 1 l – 83.5% 1.2 × 1013 1.2 × 1013
– 10 l 94.1% 8.8 × 1013 8.8 × 1012
scAAV2i8 CMV-I1c 8 × 1 l – – 1.1 × 1014 1.4 × 1013
– 10 l – 6.7 × 1013 6.7 × 1012
scAAV9 CMV-GFP 1 l – 82.4% 3.1 × 1013 3.1 × 1013
– 10 l 86.7% 2.0 × 1014 2.0 × 1013
scAAV9 CMV-I1c 6 × 1 l – – 2.1 × 1014 3.5 × 1013
– 10 l – 3.0 × 1014 3.0 × 1013
– 10 l – 2.0 × 1014 2.0 × 1013
scAAV2.5 CBh-GFP – 8.5 l 60.3% 7.2 × 1013 8.5 × 1012
scAAV9 CBh-GFP – 10 l 65.2% 1.4 × 1014 1.4 × 1013
AAV8 CMV-eGFP – 20 l – 5.5 × 1014 2.7 × 1013
scAAV8 FIX – 20 l – 3.0 × 1014 1.5 × 1013
scAAV, self-complementary recombinant adeno-associated virus.
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then resuspended in fresh media and placed back into the shaker 
incubator for continued growth and production of rAAV. Media 
samples were then taken every 24 hours and media was replaced 
every 48 hours. At the 120-hour time-point, rAAV8 and rAAV9 
titers were determined from both the media and cell pellets. As 
shown in Figure 5, rAAV8 and rAAV9 can be detected and har-
vested from the media 48 hours post-transfection with increasing 
amounts of vector found in the media as time progresses and the 
media is replaced. When comparing the total yield to the 48 hours 
cell pellet control (Figure 5), the discontinuous harvest method 
yielded 6.5- and 4.8-fold more rAAV8 and rAAV9 vector respec-
tively. This process was successfully adapted to the WAVE biore-
actor using a perfusion set up to remove cell culture media every 
24 hours for purification of rAAV followed by supplementing 
fresh media to keep the cells viable and producing rAAV. A 1 l cell 
culture in a 2 l perfusion WAVE bioreactor bag was transfected 
and 48 hours post-transfection 80% of the media was harvested 
through the perfusion filter and replaced with fresh media every 
24 hours. The harvested media containing the rAAV8 CMV-
eGFP vector was concentrated by TFF and then purified using 
the methods described. As shown in Table 3, AAV8 was purified 
from the cell culture media with yields ranging from 9 × 1012 to 
3 × 1013 total vg at each time point. The overall purified yield was 
1.1 × 1014, which included the yield from the cell pellet harvested 
and purified at 144 hours. The yield recovered from the cell pellet 
comprises only 8% of the overall yield suggesting that process-
ing the cell pellet is not necessary. Producing AAV serotypes (that 
have low binding affinity to the producer cell line) using the per-
fusion production method will allow the manufacturer to utilize 
an animal-component free suspension culture to continuously 
produce, harvest and purify rAAV from the culture media via a 
single transfection without the need to lyse cells and introduce 
additional contaminants (host cell proteins and host cell genomic 
DNA). This in turn would generate more rAAV from an equal 
amount of input plasmid than the standard production protocol 
where the production process is halted when cells are harvested 
48 hours post-transfection. This is the first report of continuous 
rAAV harvested from the cell culture media at numerous time-
points post-transfection using a scalable, animal component-free 
system, suspension HEK293 cell line, and bioreactor.
DISCUSSION
A number of phase 1 and phase 2 clinical trials utilizing AAV have 
been performed worldwide for inherited and acquired diseases.1,2 
The increase in the number of clinical trials emphasizes the need 
to establish scalable manufacturing technologies that are univer-
sal for all serotypes, GMP compliant as well as user-friendly. This 
report details a robust scalable transient transfection manufactur-
ing technology (Figure 6) using a HEK293 cell line that can grow 
in animal component-free and antibiotic-free suspension condi-
tions and generate rAAV yields per cell equivalent to the HSV 
dual infection technology8–12 and BEVS1 and superior to existing 
suspension HEK293 systems.20–22
A strategy was established early on during the development of 
this technology that influenced the choices made on reagents for 
deriving an animal component-free and antibiotic-free manufactur-
ing technology. Vigilant screening of chemically defined suspension 
media to determine derivation of components was the first step fol-
lowed by adapting the suspension HEK293 cell line to grow in these 
media. Based on cell growth characteristics, transfection efficiency 
and rAAV vector production two media were selected for further 
optimization studies13 SFM4Transfx-293 media and3 Freestyle 
F17 media. Further optimization of transfection conditions were 
assessed on these media (Figures 1 and 2) before it was determined 
that the F17 media was superior to the SFM4Transfx-293 media 
in regard to transfection efficiency and vector production for our 
specific suspension HEK293 cell clone. rAAV2 yields per cell for 
the SFM4Transfx-293 media and F17 media consistently ranged 
between 3–6 × 104 and 1–2 × 105 respectively (data not shown).
A universal purification strategy was developed using a modi-
fied step iodixanol gradient followed by a single ion exchange 
chromatography step. This purification procedure is considered 
“universal” due to its ability to purify AAV serotypes 1–6, 8, 9 and 
all University of North Carolina Gene Therapy Center chimeric 
capsids following a single protocol with no modifications due to 
differences in serotype (Figure 4a and Table 1). In addition to gen-
erating high-purity vectors, this procedure yields >90% full rAAV 
particles (Figure 4c and Table 1). The time invested to generate 
high-purity yields of rAAV using shaker flasks and WAVE bioreac-
tors is nominal, requiring only 1 to 2 weeks. Based on the doses 
used in the phase 1 Leber’s Congenital Amaurosis clinical trial,35 
a single 5 l WAVE bioreactor culture would generate several thou-
sand clinical doses (Table 2, AAV2 5 l wave run). Expanding on 
Figure 5 Continuous production and harvesting of recombinant 
adeno-associated virus (rAAV) 8 and rAAV9 from the suspension 
HEK293 culture medium. Total yield represents all media time-points 
and 120-hour cell pellet rAAV yields combined. Forty-eight hour cell pel-
let control represents the yield from a standard harvest at 48 hours post-
transfection as described in this report.
4.00E+13
3.50E+13
3.00E+13
2.50E+13
2.00E+13
To
ta
l r
AA
V 
vg
1.50E+13
1.00E+13
5.00E+12
0.00E+00
AAV8
AAV9
48 hours
media
72 hours
media
96 hours
media
120 hours
media
120 hours
cell pellet
Hours post-transfection
Continuous rAAV harvest from media
Total
yield
48 hours
cell pellet
control
Table 3 WAVE bioreactor production of rAAV8 CMV-eGFP using 
perfusion technology
Time point AAV8 purified vg:TU
48 hours 1.4 × 1013 243
72 hours 2.9 × 1013 218
96 hours 3.0 × 1013 193
120 hours 1.5 × 1013 238
144 hours 9.0 × 1012 263
144 hours cell pellet 8.6 × 1012 360
Total purified AAV8 (1 l culture) 1.1 × 1014
Average AAV8 48-hour yields 1.0–2.0 × 1013 136.3
scAAV, self-complementary recombinant adeno-associated virus.
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the utility of this manufacturing technology is its ability to generate 
and harvest AAV serotypes (with low binding affinity to HEK293 
cells) from the suspension culture media. Early studies carried out 
in 1990s by Xiao and Samulski, demonstrated that AAV particles 
were secreted in culture media.34 This uncovered anomaly was 
further characterized by Lock et al. and Vandenberghe et al. to 
illustrate the partitioning of certain AAV serotypes from the cell 
during productive infection. As an outcome, this has allowed the 
manufacturer to utilize an animal component-free/antibiotic-free 
suspension culture to continuously produce and harvest rAAV 
from the culture media via a single transfection at all scales with-
out lysing and harvesting AAV from the producer cells. This in 
turn would generate more AAV from an equal amount of trans-
fected plasmid than the standard transfection protocol where the 
production process is halted when cells are harvested 48 hours 
post-transfection without collection of the media. Yields of rAAV 
using the continuous harvest/perfusion methodology would reach 
or surpass 1 × 1015 total purified vg for some rAAV vectors from a 
10-l WAVE bioreactor culture at low cell density (total vg based on 
yields in Tables 2 and 3).
While transfection of suspension HEK293 cells requires quali-
fying plasmids for GMP production of rAAV, these reagents are 
stable over long durations. When compared to rAAV production 
systems that require infectious agents like HSV and BEVS, plasmid 
production is relatively easy, quick, and inexpensive (especially 
when the continuous harvest of AAV from suspension culture is 
utilized) to make under GMP compliance with release testing con-
ducted in a good laboratory practices setting. For both the BEVS 
and rHSV production systems, a significant amount of time, labor, 
and finances must be invested in generating and characterizing 
the vectors to generate rAAV at all scales in addition to establish-
ing master and working cell and viral banks. However, once these 
reagents are established, they are very ameanable to large-scale 
production and continue to provide the research community a 
number of viable AAV production approaches going forward. As 
with all seed stocks that are infectious in nature, potential concern 
of vector instability is carefully monitored during serial expansion 
to large volumes. For generation of baculovirus and rHSV master 
viral banks or working viral banks each expansion requires batch 
testing prior to use. Similarly to the triple transfection protocol 
presented here, optimizing these alternative AAV production 
approaches requires challenges that are being addressed currently. 
For example current rHSV-based rAAV production requires gen-
erating high-titer, infectious rHSV stocks from engineered rHSV 
vectors that are intentionally designed to be replication deficient 
that sometimes reduces the overall yield of seed stocks. As these 
and other identified rate limiting production concerns are system-
atically addressed, the AAV gene therapy community has access to 
numerous production alternatives going forward.
As described in this report, this user-friendly manufacturing 
process can easily be adapted and used in all academic AAV labo-
ratories and serve as the workhorse technology to bring additional 
investigators’ work into preclinical and clinical phases of research. 
This approach is ideally suited when efforts to optimize vector of 
choice (e.g., protmoter tweaking, optimization modifications) are 
an active process since the time from plasmid to vector is extremely 
quick. More importantly, the process of producing large quantities 
rAAV can be completed within 1–2 weeks, provides yields and puri-
ties acceptable for clinical applications and is universal with respect 
to all serotypes and chimeric capsids tested to date. With respect 
to use by numerous investigators, the manufacturing technology 
does not require the use of infectious agents or the capacity to learn 
another biological system (e.g., BEVS), but however does require an 
understanding of AAV biology and transient transfection. Currently, 
the Vector Core facility at the University of North Carolina is gener-
ating research, preclinical and clinical grade lots of rAAV using the 
manufacturing technology detailed in this report. Greater than 100 
large-scale research and preclinical lots of different rAAV serotypes 
have been administered into mice, rats, cats, dogs, pigs, horses, and 
nonhuman primates. Several cGMP phase 1 clinical manufacturing 
Figure 6 Depiction of recombinant adeno-associated virus (rAAV) manufacturing technology. (1) Suspension HEK293 cells in the WAVE biore-
actor 20/50EHT are transfected. (2) Approximately 48 hours post-transfection, cells are harvested into centrifuge bottles and pelleted at low-speed 
centrifugation. (3) Cell pellets are resuspended and then lysed using a sonicator. (4) Lysate is incubated with Benzonase for 45 minutes at 37 °C. (5) 
Lysate is clarified using low-speed centrifugation. (6) Clarified lysate is loaded onto iodixanol gradient and ultracentrifuged. (7) rAAV collected from 
the 40%/60% iodixanol interface are loaded onto AKTA FPLC and purified using anion exchange chromatography. (8) rAAV chromatography peak 
fractions are dialyzed into final formulation buffer. (9) Sterile filtration through 0.2 μm filter.
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campaigns have been successfully carried out using the manufactur-
ing technology including ongoing scAAV8 FIX clinical trial carried 
out by Baxalta. As the described transfection-based scalable manu-
facturing technology is further developed, manufacturing capacities 
and efficiencies will increase in addition to critical starting reagents 
(input plasmids, transfection reagent, and media) and overall cost of 
manufacturing will decrease. Our recent transfection experiments 
utilizing a modestly higher cell density (4 × 106 cells/ml) conducted 
in small scale shaker flasks and 3 l stir tank biroeactors demonstrated 
a linear increase in vector production (~1 × 1015 vg/l of lysate) using 
less than-linear plasmid amount (data not shown). Optimization of 
feed strategies for high cell density (~1 × 107 cells/ml) transfection 
and AAV vector manufacturing are currently underway in addition 
to an optimized centrifugation-free, scalable purification process 
to accommodate larger batch sizes of 250 l or greater. This coupled 
with the AAV perfusion approach described above allowing one to 
generate essentially 5–10× amount of vector from same amount of 
starting plasmid suggest that current improvement of AAV vector 
production is on stable footing and transition to clinical demand 
should become routine due to user friendly protocols such as the 
one described here.
MATERIALS AND METHODS
Derivation of suspension HEK293 cells from an adherent HEK293 quali-
fied master cell bank. The derivation of the suspension cell line from the 
parental HEK293 master cell bank (MCB) was performed in a Class 10,000 
clean room facility. The derivation of the suspension cell line was carried 
out in a two-phase process that involved first weaning the cells off of media 
containing bovine serum and then adapting the cells to SFM4Transfx-293 
serum-free suspension media (Hyclone, Logan, UT). The suspension cell 
line was created as follows. First, a vial of qualified master cell bank was 
thawed and placed into culture in Dulbecco's modified Eagle's medium con-
taining 10% fetal bovine serum and cultured for several days to allow the 
cells to recover from the freeze/thaw cycle. The MCB cells were cultured 
and passaged over a 4-week period while the amount of fetal bovine serum 
in the DMEM was gradually reduced from 10 to 2.5%. The cells were then 
transferred from DMEM 2.5% fetal bovine serum into SFM4Transfx-293 
serum-free suspension media and grown in shaker flasks. The cells were 
then cultured in the SFM4Transfx-293 media for another 3 weeks while 
their growth rate and viability were monitored. The adapted cells were then 
expanded and frozen down. A number of vials from this cell bank were sub-
sequently thawed and used during process development studies to create a 
scalable manufacturing process using shaker flasks and wave bioreactor sys-
tems to generate rAAV vectors. Suspension HEK293 cells were maintained 
in serum-free suspension F17 media (Thermo Fisher Scientific, Waltham, 
MA) that supports both growth and high transfection efficiency in shaker 
flasks and WAVE bioreactor bags. Multitron Shaker Incubators (Infors USA 
Inc., Laurel, MD) were used for maintenance of the cells and generation of 
rAAV vectors at specific rpm shaking speeds (based on cell culture volumes), 
80% humidity, and 5% CO2. Cells were passaged and maintained between 
densities of 2 × 105 viable cells/ml and 3.5 × 106 viable cells per ml. Cell via-
bilities of > 95% were obtained consistently during routine cell passaging.
Transfection of suspension HEK293 cells (optimized protocol). On the day 
of transfection, the cells were counted using a ViCell XR Viability Analyzer 
(Beckman Coulter) and diluted to 1 × 106 viable cells/ml. To mix the trans-
fection cocktail, the following reagents were added in this order: plasmid 
DNA (CsCl purified), Optimem (Thermo Fisher Scientific), Optipro or 
F17 media, Polyethyleneimine Max (MW 25,000). The plasmid DNA was 
used in a ratio of 2:1.5:1 for pXX680:pXR2:TR plasmid and 1.5 µg total 
plasmid was used per 1 × 106 total cells. The pXR series of helper plasmids 
were used in these studies to generate multiple rAAV serotype vectors.36 
PEI Max was used at a PEI:DNA ratio of 2:1. Optimem I, Optipro, or F17 
media was added such that the entire transfection mix cocktail made up 
5% of the total flask final volume. The cocktail was vortexed for 5–10 sec-
onds prior to being incubated at RT for 10–15 minutes. The transfection 
cocktail was then pipetted into the flasks and placed back in the shaker/
incubator. Three hours post-transfection, the flasks were supplemented 
with CDM4HEK293 media (HyClone, Logan, UT) at 10% of final total 
cell culture volume to halt the transfection and prevent further PEI-related 
cell aggregation. All optimization studies were carried out at 30 ml culture 
volumes followed by validation at larger culture volumes. Cells were har-
vested 48 hours post-transfection with viabilities ranging between 75 and 
90% depending on input plasmids.
Production of rAAV using WAVE bioreactor systems. WAVE bioreac-
tor bags were seeded at a volume that was 2.5-fold less than the maxi-
mum cell culture volume of the WAVE bag. For example, 2 and 4 l for 
10 and 20 l WAVE bioreactor bags respectively. Seeding cell density was 
between 7 × 105 and 9 × 105 viable cells/ml. The F17 media was supple-
mented with 0.2% Pluronic-F68 to allow for growth in WAVE bioreactor 
bags. Two days postseeding, the WAVE bioreactor bag, cell culture counts 
were taken and the cell culture was then expanded to 85% of the final cell 
culture volume. The WAVE bioreactor cell culture was then transfected. 
The transfection cocktail mix contains the following with a final volume 
of 5% of the final cell culture volume in the WAVE bioreactor bag: 1.5 
μg of DNA/ml of cell culture, 2:1.5:1 plasmid ratios of XX680:pXR:TR 
plasmid, Polyethyleneimine Max (Polysciences) to DNA ratio of 2:1 and 
Opti-Mem I media (Thermo Fisher Scientific), Optipro (Thermo Fisher 
Scientific) or F17 media. After 10–15-minute incubation at room tem-
perature, the transfection cocktail is pumped into the WAVE bioreactor 
bag. Three hours post-transfection, CDM4HEK293 media (HyClone) was 
pumped in at a volume of 10% of the final volume of cell culture. Cell 
culture was harvested from the WAVE bioreactor bag at least 48 hours 
post-transfection.
Analyzing transfection efficiency/GFP expression using flow cytom-
etry. Approximately 24 hours post-transfection, 1 ml of cell culture was 
removed from each flask or WAVE bioreactor bag as well as an untrans-
fected control. Samples were analyzed using a Dako Cyan (Carpinteria, 
CA) flow cytometer.
Harvesting suspension HEK293 cells from shaker flasks and WAVE bio-
reactor bags. Fourty-eight hours post-transfection, cell cultures were col-
lected into 500 ml polypropylene conical tubes (Corning, Corning, NY) 
either by pouring from shaker flasks or pumping from WAVE bioreactor 
bags. The cell culture was then centrifuged at 655 × g for 10 minutes using a 
Sorvall RC3C plus centrifuge and H6000A rotor. The supernatant was dis-
carded, the cells were resuspended in 1× phosphate-buffered saline, trans-
ferred to a 50 ml conical tube and centrifuged at 655 × g for 10 minutes. At 
this point, the pellet could either be stored in a −80 °C freezer or continued 
through purification.
Titering rAAV from cell lysate using qPCR. Ten milliliters of cell culture 
were removed and centrifuged at 655 × g for 10 minutes using a Sorvall 
RC3C plus centrifuge and H6000A rotor. The supernatant was decanted 
from the cell pellet. The cell pellet was then resuspended in 5 ml of DNase 
buffer (5 mmol/l CaCl2, 5 mmol/l MgCl2, 50 mmol/l Tris-HCl pH 8.0) fol-
lowed by sonication to lyse the cells efficiently. Three hundred microliters 
were then removed and placed into a 1.5 ml microfuge tube. One hundred 
and forty units of DNaseI were then added to each sample and incubated 
at 37 °C for 1 hour. To determine the effectiveness of the DNase digestion, 
4–5 µg of TReGFP plasmid was spiked into a nontransfected cell lysate with 
and without the addition of DNase. Fifty microliters of ethylenediamine-
tetraacetic acid (EDTA)/Sarkosyl solution (6.3% sarkosyl, 62.5 mmol/l 
EDTA pH 8.0) were then added to each tube and incubated at 70 °C for 
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20 minutes. Fifty microliters of Proteinase K (10 mg/ml) were then added 
and incubated at 55 °C for at least 2 hours. Samples were then boiled for 15 
minutes to inactivate the Proteinase K. An aliquot was removed from each 
sample to be analyzed by qPCR. Two qPCR reactions were carried out in 
order to effectively determine how much rAAV vector was generated per 
cell. One qPCR reaction was set up using a set of primers designed to bind 
to a homologous sequence on the backbones of plasmids XX680, pXR2, 
and TReGFP. The second qPCR reaction was set up using a set of primers 
to bind and amplify a region within the eGFP gene. qPCR is conducted 
using Sybr green reagents and Light cycler 480 from Roche. Samples are 
denatured at 95 °C for 10 minutes followed by 45 cycles (90 °C for 10 sec-
onds, 58 °C for 10 seconds, and 72 °C for 10 seconds) and melting curve (1 
cycle 99 °C for 30 seconds, 65°C for 1 minute continuous).
Purification of rAAV from crude lysate. Each cell pellet was adjusted to a 
final volume of 10 ml using ddH2O. The pellets were vortexed briefly and 
sonicated for 4 minutes at 30% amplitude in 1 second on, 1 second off inter-
vals. After sonication, 550 U of DNase was added and incubated at 37 °C 
for 45 minutes. Three hundred microliters of 5M NaCl were added to the 
pellets to free any virus bound/interacting to the cell debris and then briefly 
vortexed. The pellets were then centrifuged at 9,400 × g using the Sorvall 
RC5B centrifuge and HS-4 rotor to pellet the cell debris and the clarified 
lysate was transferred to a Type70Ti centrifuge tube (Beckman 361625).
Discontinuous iodixanol gradient. Iodixanol concentrations were made 
according to the protocol established by Zolothukin et al.28 substituting 
Tris pH 9.0 to a final concentration of 25 mmol/l instead of 1× phosphate-
buffered saline. 17, 25, 40, and 60% at 6, 6, 7, and 5 ml, respectively under-
layered the clarified lysate using a Watson Marlow peristaltic pump at 
35 rpm to form the discontinuous gradient. The gradients were then cen-
trifuged at 70K for 1 hour in a Type70Ti rotor (Beckman). After centrifu-
gation, the tubes were removed and the 40% layer was extracted using a 
10 ml syringe and 18-gauge needle.
Ion exchange chromatography. Using an AKTA FPLC (GE Healthcare, 
Little Chalfont, Buckinghamshire, UK), 1 ml Q Hyper-D columns (Pall) 
were equilibrated with 10 ml of 0.5M NaOH followed by 10 ml 2M NaCl 
in 25 mmol/l Tris pH 9.0 (Buffer B), and finally 20 ml of 25 mmol/l Tris 
pH9.0 (Buffer A). The extracted iodixanol fraction was adjusted to a 
specific volume with Buffer A, then loaded onto AKTA FPLC at 0.5 ml/
minute and unbound sample was washed with 7 ml of Buffer A. The elu-
tion consisted of a 4 part step gradient using Buffer B at 12.5, 25, 50, and 
100% intervals in 10 ml steps. When larger rAAV preparations were gen-
erated, the 5 ml HiTrap Q HP columns (GE Healthcare) were utilized for 
purification.
Dialysis of purified rAAV. Anion exchange chromatography peak fractions 
were dialyzed at 4 °C overnight into a buffer composed of 1× phosphate-
buffered saline, 5% Sorbitol, and 350 mmol/l NaCl.
Titering rAAV using dot blot. Hundred microliters of DNase buffer (140 
units DNase, 5 mmol/l CaCl2, 5 mmol/l MgCl2, 50 mmol/l Tris-HCl pH 8.0) 
were added to each well of a 96-well microtiter plate. One to three microliters 
or serial dilutions of virus were added to each well and incubated at 37 °C for 
30 minutes. The samples were then supplemented with 15 µl Sarkosyl/EDTA 
solution (6.3% sarkosyl, 62.5 mmol/l EDTA pH 8.0) and placed at 70 °C for 
20 minutes. Next, 15 µl of Proteinase K (10 mg/ml) was added and incubated 
at 50 °C for at least 2 hours. One hundred and twenty-five microliters of 
NaOH buffer (80 mmol/l NaOH, 4 mmol/l EDTA pH 8.0) were added to 
each well. A series of transgene specific standards were created through a 
dilution series. NaOH buffer was then added and incubated. Nylon mem-
brane was incubated at RT in 0.4M Tris-HCl, pH 7.5 and then set up on 
the dot blot apparatus. After a 10–15-minute incubation in NaOH buffer, 
the samples and standards were loaded into the dot blot apparatus onto 
the GeneScreen PlusR hybridization transfer membrane (PerkinElmer). 
The sample was then applied to the membrane using a vacuum. The nylon 
membrane was soaked in 0.4M Tris-HCl, pH 7.5 and then crosslinked using 
UV strata linker 1800 (Stratagene, La Jolla, CA) at 60,000 ujoules. The mem-
brane was prehybridized in CHURCH buffer (1% BSA, 7% sodium dodecyl 
sulfate, 1 mmol/l EDTA, 0.5M Na3PO4, pH 7.5). After prehybridization, the 
membrane was hybridized overnight with a 32P CTP-labeled transgene probe 
(Roche Random Prime DNA labeling kit). The following day, the membrane 
was washed with low stringency saline sodium citrate buffer (1× saline 
sodium citrate, 0.1% sodium dodecyl sulfate) and high stringency (0.1× 
saline sodium citrate, 0.1% sodium dodecyl sulfate). It was then exposed on 
a phosphorimager screen and analyzed for densitometry using a STORM840 
scanner (GE Healthcare, Little Chalfont, Buckinghamshire, UK).
Analyzing rAAV vector purity using silver stain method. Samples from 
purified vector were loaded onto NuPage 10% Bis-Tris gels (Invitrogen) 
and run using 1× NuPage running buffer. Typically, 1 × 1010 genome 
containing particles were loaded per well. The gels were treated with 
SilverXpress Silver staining kit #LC6100 (Invitrogen).
Analysis of self-complementary genomes using alkaline gel electropho-
resis and Southern blot. Briefly, purified self-complementary rAAV was 
added to 200 µl of DNase I buffer (140 units DNase, 5 mmol/l CaCl2, 5 
mmol/l MgCl2, 50 mmol/l Tris-HCl pH 8.0) incubated at 37 °C for 60 
minutes, followed by inactivation of the DNase by adding 30 µl of EDTA 
Sarkosyl/EDTA solution (6.3% sarkosyl, 62.5 mmol/l EDTA pH 8.0) 
and placed at 70 °C for 20 minutes. Twenty microliters of Proteinase K 
(10 mg/ml) were then added to the sample and incubated for a minimum 
of 2 hours at 50 °C. Phenol/chloroform was added in a 1:1 ratio, followed 
by ethanol precipitation of the viral vector DNA. The pelleted DNA was 
then resuspended in alkaline buffer (50 mmol/l NaOH, 1 mmol/l EDTA) 
for denaturation, loaded onto a 1% alkaline agarose gel, and run at 25V 
overnight at 4 °C. The gel was then equilibrated in alkaline transfer buffer 
(0.4 M NaOH, 1M NaCl) and a Southern blot was performed for 8 hours 
to overnight transfer of the vector DNA to a GeneScreen PlusR hybridiza-
tion transfer membrane (PerkinElmer, Waltham, MA). The membrane was 
then neutralized using 0.5 M Tris pH 7.5 with 1M NaCl, and was hybrid-
ized overnight with a 32P CTP-labeled transgene probe. After washing the 
membrane as previously described, the membrane was exposed to a phos-
phorimager screen and analyzed using a STORM840 scanner.
Preparing samples for mass spectrometry. Twenty microliters of the elu-
tion fraction containing the identified contaminant were loaded onto a 10% 
Bis/Tris gel (Invitrogen) using a 1× 3-(N-morpholino)propanesulfonic acid 
buffer/sodium dodecyl sulfate running buffer (Invitrogen). The gel was then 
stained with Coomassie Brilliant Blue R250 (Bio-Rad) to visualize the con-
taminant around 25 kDa. The contaminant was then removed from the gel 
using a razor blade and stored in 250 μl dH2O. The sample was shipped to 
Applied Biomics for tryptic digestion and sequencing.
Transduction assays. HeLaRC-32 cells30 were plated at 2 × 105 cells/well of 
a 24-well plate and incubated at 37 °C overnight. The cells were observed 
for 90–100% confluence. Fifty milliliters of DMEM with 2% fetal bovine 
serum, 1% Pen/Strep were prewarmed, and Adenovirus (dl309) was added 
at an MOI of 10. The dl309 containing media was aliquoted in 900 µl frac-
tions and used to dilute the rAAV in a series of 10-fold dilutions. The rAAV 
was then plated at 400 µl and allowed to incubate for 48 hours at 37 °C. For 
rAAV containing the eGFP transgene, the GFP-positive cells were counted 
using fluorescence microscopy. Transducing units (TU) are then calculated 
based upon the dilution and multiplying the average number of counts/
field by the total number of fields per well at the specific magnification.
TEM of negatively stained rAAV particles. Electron microscopy allows a 
direct visualization of the viral particles. Purified dialyzed rAAV vectors 
were placed on a 400-mesh glow-discharged carbon grid by inversion of 
the grid on a 20 µl drop of virus. The grid was then washed two times by 
inversion on a 20 µl drop of ddH2O followed by inversion of the grid onto 
a 20 µl drop of 2% uranyl acetate for 30 seconds. The grids were blotted dry 
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by gently touching the edges of the grids to whattman paper. Each vector 
was visualized using a Zeiss EM 910 electron microscope.
ACKNOWLEDGMENTS
This project was funded by North Carolina Biotechnology Center 
2007-CFG-8012. J.C.G. holds patents that have been licensed by 
University of North Carolina to Asklepios Biopharmaceutical, for which 
he receives royalties. He has consulted for Asklepios Biopharmaceutical 
and has received payment for consultation. R.J.S. is the founder and 
a shareholder at Asklepios BioPharmaceutical. He receives research 
support through the University of North Carolina from Asklepios 
BioPharmaceutical. He holds patents that have been licensed by UNC 
to Asklepios Biopharmaceutical, for which he receives royalties. He 
has consulted for Baxter Healthcare and has received payment for 
speaking.
REFERENCES
 1. Aucoin, MG, Perrier, M and Kamen, AA (2008). Critical assessment of current adeno-
associated viral vector production and quantification methods. Biotechnol Adv 26: 73–88.
 2. Mueller, C and Flotte, TR (2008). Clinical gene therapy using recombinant adeno-
associated virus vectors. Gene Ther 15: 858–863.
 3. Atchison, RW, Casto, BC and Hammon, WM (1965). Adenovirus-associated defective 
virus particles. Science 149: 754–756.
 4. Buller, RM, Janik, JE, Sebring, ED and Rose, JA (1981). Herpes simplex virus 
types 1 and 2 completely help adenovirus-associated virus replication. J Virol 40: 
241–247.
 5. Xiao, X, Li, J and Samulski, RJ (1998). Production of high-titer recombinant adeno-
associated virus vectors in the absence of helper adenovirus. J Virol 72: 2224–2232.
 6. Grimm, D, Kern, A, Rittner, K and Kleinschmidt, JA (1998). Novel tools for production 
and purification of recombinant adenoassociated virus vectors. Hum Gene Ther 9: 
2745–2760.
 7. Matsushita, T, Elliger, S, Elliger, C, Podsakoff, G, Villarreal, L, Kurtzman, GJ et al. 
(1998). Adeno-associated virus vectors can be efficiently produced without helper 
virus. Gene Ther 5: 938–945.
 8. Booth, MJ, Mistry, A, Li, X, Thrasher, A and Coffin, RS (2004). Transfection-free and 
scalable recombinant AAV vector production using HSV/AAV hybrids. Gene Ther 11: 
829–837.
 9. Conway, JE, Rhys, CM, Zolotukhin, I, Zolotukhin, S, Muzyczka, N, Hayward, GS et 
al. (1999). High-titer recombinant adeno-associated virus production utilizing a 
recombinant herpes simplex virus type I vector expressing AAV-2 Rep and Cap. Gene 
Ther 6: 986–993.
 10. Hwang, KK, Mandell, T, Kintner, H, Zolotukhin, S, Snyder, R and Byrne, BJ (2003). 
High titer recombinant adeno-associated virus production using replication deficient 
herpes simplex viruses type 1. Mol Ther 7: S14–S15.
 11. Kang, W, Wang, L, Harrell, H, Liu, J, Thomas, DL, Mayfield, TL et al. (2009). An 
efficient rHSV-based complementation system for the production of multiple rAAV 
vector serotypes. Gene Ther 16: 229–239.
 12. Thomas, DL, Wang, L, Niamke, J, Liu, J, Kang, W, Scotti, MM et al. (2009). 
Scalable recombinant adeno-associated virus production using recombinant herpes 
simplex virus type 1 coinfection of suspension-adapted mammalian cells. Hum Gene 
Ther 20: 861–870.
 13. Aslanidi, G, Lamb, K and Zolotukhin, S (2009). An inducible system for highly efficient 
production of recombinant adeno-associated virus (rAAV) vectors in insect Sf9 cells. 
Proc Natl Acad Sci USA 106: 5059–5064.
 14. Cecchini, S, Negrete, A and Kotin, RM (2008). Toward exascale production of 
recombinant adeno-associated virus for gene transfer applications. Gene Ther 15: 
823–830.
 15. Kohlbrenner, E, Aslanidi, G, Nash, K, Shklyaev, S, Campbell-Thompson, M, Byrne, BJ 
et al. (2005). Successful production of pseudotyped rAAV vectors using a modified 
baculovirus expression system. Mol Ther 12: 1217–1225.
 16. Negrete, A and Kotin, RM (2008). Large-scale production of recombinant adeno-
associated viral vectors. Methods Mol Biol 433: 79–96.
 17. Negrete, A, Yang, LC, Mendez, AF, Levy, JR and Kotin, RM (2007). Economized 
large-scale production of high yield of rAAV for gene therapy applications exploiting 
baculovirus expression system. J Gene Med 9: 938–948.
 18. Urabe, M, Ding, C and Kotin, RM (2002). Insect cells as a factory to produce adeno-
associated virus type 2 vectors. Hum Gene Ther 13: 1935–1943.
 19. Urabe, M, Nakakura, T, Xin, KQ, Obara, Y, Mizukami, H, Kume, A et al. (2006). 
Scalable generation of high-titer recombinant adeno-associated virus type 5 in insect 
cells. J Virol 80: 1874–1885.
 20. Durocher, Y, Pham, PL, St-Laurent, G, Jacob, D, Cass, B, Chahal, P et al. (2007). 
Scalable serum-free production of recombinant adeno-associated virus type 2 by 
transfection of 293 suspension cells. J Virol Methods 144: 32–40.
 21. Hildinger, M, Baldi, L, Stettler, M and Wurm, FM (2007). High-titer, serum-free 
production of adeno-associated virus vectors by polyethyleneimine-mediated 
plasmid transfection in mammalian suspension cells. Biotechnol Lett 29: 1713–1721.
 22. Park, JY, Lim, BP, Lee, K, Kim, YG and Jo, EC (2006). Scalable production of adeno-
associated virus type 2 vectors via suspension transfection. Biotechnol Bioeng 94: 
416–430.
 23. Grieger, JC, Choi, VW and Samulski, RJ (2006). Production and characterization of 
adeno-associated viral vectors. Nat Protoc 1: 1412–1428.
 24. Thomas, M, Lu, JJ, Ge, Q, Zhang, C, Chen, J and Klibanov, AM (2005). Full 
deacylation of polyethylenimine dramatically boosts its gene delivery efficiency and 
specificity to mouse lung. Proc Natl Acad Sci USA 102: 5679–5684.
 25. Davidoff, AM, Ng, CY, Sleep, S, Gray, J, Azam, S, Zhao, Y et al. (2004). Purification of 
recombinant adeno-associated virus type 8 vectors by ion exchange chromatography 
generates clinical grade vector stock. J Virol Methods 121: 209–215.
 26. Kaludov, N, Handelman, B and Chiorini, JA (2002). Scalable purification of adeno-
associated virus type 2, 4, or 5 using ion-exchange chromatography. Hum Gene Ther 
13: 1235–1243.
 27. Zolotukhin, S, Potter, M, Zolotukhin, I, Sakai, Y, Loiler, S, Fraites, TJ Jr et al. (2002). 
Production and purification of serotype 1, 2, and 5 recombinant adeno-associated 
viral vectors. Methods 28: 158–167.
 28. Zolotukhin, S, Byrne, BJ, Mason, E, Zolotukhin, I, Potter, M, Chesnut, K et al. (1999). 
Recombinant adeno-associated virus purification using novel methods improves 
infectious titer and yield. Gene Ther 6: 973–985.
 29. McCarty, DM, Monahan, PE and Samulski, RJ (2001). Self-complementary 
recombinant adeno-associated virus (scAAV) vectors promote efficient transduction 
independently of DNA synthesis. Gene Ther 8: 1248–1254.
 30. Chadeuf, G, Favre, D, Tessier, J, Provost, N, Nony, P, Kleinschmidt, J et al. (2000). 
Efficient recombinant adeno-associated virus production by a stable rep-cap HeLa 
cell line correlates with adenovirus-induced amplification of the integrated rep-cap 
genome. J Gene Med 2: 260–268.
 31. Sonntag, F, Schmidt, K and Kleinschmidt, JA (2010). A viral assembly factor 
promotes AAV2 capsid formation in the nucleolus. Proc Natl Acad Sci USA 107: 
10220–10225.
 32. Lock, M, Alvira, M, Vandenberghe, LH, Samanta, A, Toelen, J, Debyser, Z et al. (2010). 
Rapid, simple, and versatile manufacturing of recombinant adeno-associated viral 
vectors at scale. Hum Gene Ther 21: 1259–1271.
 33. Vandenberghe, LH, Xiao, R, Lock, M, Lin, J, Korn, M and Wilson, JM (2010). Efficient 
serotype-dependent release of functional vector into the culture medium during 
adeno-associated virus manufacturing. Hum Gene Ther 21: 1251–1257.
 34. Xiao, X (1992). Characterization of adeno-associated virus replication and integration. 
Ph.D. Thesis. Univ. Pittsburgh.
 35. Maguire, AM, Simonelli, F, Pierce, EA, Pugh, EN Jr, Mingozzi, F, Bennicelli, J et al. 
(2008). Safety and efficacy of gene transfer for Leber’s congenital amaurosis. N Engl J 
Med 358: 2240–2248.
 36. Rabinowitz, JE, Rolling, F, Li, C, Conrath, H, Xiao, W, Xiao, X et al. (2002). Cross-
packaging of a single adeno-associated virus (AAV) type 2 vector genome into 
multiple AAV serotypes enables transduction with broad specificity. J Virol 76: 
791–801.
Molecular Therapy vol. 24 no. 2 feb. 2016 297
